scispace - formally typeset
N

Nan Lin

Researcher at Harvard University

Publications -  1220
Citations -  65601

Nan Lin is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 105, co-authored 687 publications receiving 54545 citations. Previous affiliations of Nan Lin include University of Michigan & Fujian Medical University.

Papers
More filters
Journal ArticleDOI

Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.

TL;DR: The results of this cohort study did not support the interpretation of ERBB2-low breast cancer as a distinct biologic subtype and suggested that, given the worse prognosis of ER-low tumors, they may be associated with confounding of prognostic analyses of ER BB2- low expression.
Journal ArticleDOI

The Weaknesses of Civic Territorial Organizations: Civic Engagement and Homeowners Associations in Urban China

TL;DR: Wang et al. as mentioned in this paper show that homeowners' civic engagement, a necessary condition for the development of homeowners associations, is inadequate across urban communities. But, the lack of awareness of partitioned property ownership, the hidden costs of civic engagement and deficiency in social capital are the main obstacles that impede homeowners' participation in neighborhood development.
Journal ArticleDOI

Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study.

TL;DR: Study results established the feasibility of using MR angiography to quantify vessel shape changes during therapy and suggest that changes in vessel tortuosity might enable early prediction of tumor treatment response.
Journal ArticleDOI

Increased Risk of Intraoperative Awareness in Patients with a History of Awareness

TL;DR: Surgical patients with a history of AWR are five times more likely to experience AWR than similar patients without a historyof AWR, and further consideration should be given to modifying perioperative care and postoperative evaluation.
Journal ArticleDOI

YiXin-Shu, a ShengMai-San-based traditional Chinese medicine formula, attenuates myocardial ischemia/reperfusion injury by suppressing mitochondrial mediated apoptosis and upregulating liver-X-receptor α

TL;DR: Analysis of the nature and underlying mechanisms of the effects of YiXin-Shu (YXS), an antioxidant-enriched TCM formula, on myocardial ischemia/reperfusion (MI/R) injury shows that YXS is effective in mitigating MI/R injury by suppressing mitochondrial mediated apoptosis and oxidative stress and by upregulating LXRα.